None listed
Conditions
Brief summary
Depression is one of the leading health burdens in New Zealand. Currently prescribed medicines are ineffective in approximately one third of patients and so new treatments are needed. Some clinical trials indicate that the anti-nausea drug scopolamine may have anti-depressant effects. In this study we are investigating the pharmacokinetics and pharmacodynamic effects of scopolamine in healthy volunteers at doses similar to that being used in studies of depression to understand the effects of scopolamine on brain function
Sponsors
The University of Auckland
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject)
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
• Male or female, aged 18 years or above and less than 60. • In the Investigators’ opinion, is able and willing to comply with all trial requirements. • Participant is willing and able to give informed consent for participation in the trial.
Exclusion criteria
• Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. • Regular use of any medication deemed to be contraindicating as judged by the attending study clinicians. • Contraindication to the use of scopolamine or glycopyrrolate according to manufacturer guideline • Significant renal or hepatic impairment. • Participants with glaucoma • Cardiovascular conditions including abnormal heart rate and blood pressure checked at screening. • History of psychiatric illness. • Any unstable medical or neurologic condition. • Problematic substance dependence in previous 3 months • Inability to speak or read English. • Any other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the trial.
Outcome results
None listed